Design Therapeutics, Inc. (DSGN) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- US stock futures rise as investors assess Democrats' midterm sweep
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DSGN Hot Sheet
Join SI Premium – FREE
Design Therapeutics, Inc. (NASDAQ: DSGN) reported Q4 EPS of ($0.21), $0.10 better than the analyst estimate of ($0.31).
For earnings history and earnings-related data on Design Therapeutics, Inc. (DSGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber (UBER) Tops Q3 EPS by 2c, Beats on Revenue; Offers Guidance
- Camtek Ltd (CAMT) Reports In-Line Q3 EPS, Beats on Revenue; Offers FY26 Revenue Guidance
- Trex (TREX) Tops Q3 EPS by 7c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
